Leading Mid-Atlantic Insurance Provider Publishes New Coverage Policy for Nerivio® REN Wearable, Granting 3.4 million People with Access to Drug

New policy recognizes the Nerivio REN wearable as medically necessary for both acute and preventive treatment of migraine in patients 8 years and older

BRIDGEWATER, N.J. and NETANYA, Israel, Dec. 3, 2025 /PRNewswire/ -- Theranica , a neuromodulation therapeutics company developing drug-free treatments for idiopathic pain conditions, today announced that a leading mid-Atlantic health insurer has published a new coverage policy for the Nerivio® remote electrical neuromodulation (REN) wearable, enabling reimbursed access to approximately 3.4 million members in Maryland, District of Columbia (Washington, D.C.) and Northern Virginia.

Already in effect since Sept. 1, the new policy recognizes the Nerivio REN wearable as medically necessary for both the acute and preventive treatment of migra